Mouse models of genetically heterogeneous multiple myeloma reveal mechanisms of immune evasion that predict clinical immunotherapy responses. Mouse models of genetically heterogeneous multiple myeloma reveal mechanisms of immune evasion that predict clinical immunotherapy responses

Data from engineered fifteen mouse strains fully encompassing MM genetic heterogeneity that recapitulate the key pathogenic elements in human MM development and multiple myeloma patients. Overall design: RNA-seq was performed in isolated BM GFP+CD138+B220- PCs from mice at MGUS (n=25) and MM (n=40) stages, and in BM CD38+CD138+ PCs from patients with newly diagnosed MGUS (n=9) and MM (n=43). As controls, BM PCs and spleen B220+CD38-FAS+ germinal center B cells were isolated from T-cell immunized 6 month-old YFP+cγ1-cre mice (n=6). In addition, human CD38+CD138+ PCs were isolated from BM aspirates in healthy donors (n=7). ***Raw data for human samples are unavailable due to legal restrictions***